The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue.
The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue.
复制标题
癌症治疗贫血功能评估 (FACT-An) 量表：评估癌症贫血和疲劳结果的新工具。
DOI：
--
复制
发表时间：
1997
期刊：
影响因子：
--
通讯作者：
D. Cella
中科院分区：
文献类型：
--
作者：
D. Cella
贫血通常与癌症和癌症治疗相关，它会产生多种降低整体生活质量 (QOL) 的症状。疲劳是癌症患者最常见的症状，会严重影响他们的日常生活。使用测量一般生活质量的癌症治疗功能评估 - 一般 (FACT-G) 工具作为核心调查问卷，开发了 20 个与疲劳和其他贫血相关症状对癌症患者的影响相关的新问题。制定了两种新工具：FACT-疲劳 (FACT-F)，由 FACT-G 加上 13 个疲劳项目（疲劳分量表）组成；FACT-贫血 (FACT-An)，由 FACT-F 加上 7 个项目组成，解决与贫血相关但与疲劳无关的其他问题。 FACT-F 和 FACT-An 表现出良好的稳定性（两者的 r = 0.87）和很强的内部一致性（分别为 alpha = 0.95 和 0.96）。疲劳分量表和非疲劳项目的重测信度系数也表现出良好的稳定性（r = .84 至 .90），疲劳分量表显示出很强的内部一致性（alpha = .93 至 .95）。收敛和判别效度测试显示，与其他已知的疲劳指标呈显着正相关，与活力呈显着负相关，并且与社会期望值缺乏预期关系。研究发现，FACT-An、FACT-F 和疲劳分量表能够根据血红蛋白 (Hb) 水平和东部肿瘤合作组 (ECOG) 表现状态成功区分患者。当根据 Hb 水平将患者分为两组时，Hb 水平大于 12 g/dL 的患者报告疲劳明显减轻，非疲劳性贫血症状减少，身体健康状况更好，功能健康状况更好，总体生活质量更高。 FACT-An、FACT-F 和疲劳分量表是癌症患者生活质量的有用衡量标准，并让人们更加关注贫血和疲劳等广泛的临床问题。
Anemia, frequently associated with cancer and cancer treatment, can use a variety of symptoms that diminish overall quality of life (QOL). Fatigue is the most commonly reported symptom among cancer patients and can significantly affect their daily lives. Using the Functional Assessment of Cancer Therapy-General (FACT-G) instrument, which measures general QOL, as a core questionnaire, 20 new questions related to the impact of fatigue and other anemia-related symptoms on patients with cancer were developed. Two new instruments were produced: the FACT-Fatigue (FACT-F), consisting of the FACT-G plus 13 fatigue items (the Fatigue Subscale), and the FACT-Anemia (FACT-An), consisting of the FACT-F plus seven items addressing other concerns related to anemia, but unrelated to fatigue. FACT-F and FACT-An demonstrated good stability (r = .87 for both) and strong internal consistency (alpha = .95 and .96, respectively). Test-retest reliability coefficients for the Fatigue Subscale and nonfatigue items also showed good stability (r = .84 to .90), and the Fatigue Subscale showed strong internal consistency (alpha = .93 to .95). Convergent and discriminant validity testing revealed a significantly positive relationship with other known measures of fatigue, a significant negative relationship with vigor, and an anticipated lack of relationship with social desirability. The FACT-An, FACT-F, and Fatigue Subscale were found to successfully discriminate patients based on hemoglobin (Hb) level and Eastern Cooperative Oncology Group (ECOG) performance status. When patients were divided into two groups by Hb levels, patients with Hb levels greater than 12 g/dL reported significantly less fatigue, fewer nonfatigue anemia symptoms, better physical well-being, better functional well-being, and higher general QOL. The FACT-An, the FACT-F, and the Fatigue Subscale are useful measures of QOL in cancer patients and add focus to the widespread clinical problems of anemia and fatigue.